Literature DB >> 30742060

A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing: a retrospective study on 5277 patients.

Xu-Hai Tan1, Xiao-Wei Zhang2, Xiao-Yun Wang2, Xiang-Qian He3, Chu Fan3, Tie-Wei Lyu1, Jie Tian4.   

Abstract

Accurate evaluation of individual risk of intravenous immunoglobin (IVIG)-resistance is critical for adopting regimens for the first treatment and prevention of coronary artery lesions (CALs) in patients with Kawasaki disease (KD).
METHODS: The KD patients hospitalized in Chongqing Children's Hospital, in west China, from October 2007 to December 2017 were retrospectively reviewed. Data were collected and compared between IVIG-resistant group and IVIG-responsive group. The independent risk factors were determined using multivariate regression analysis. A new prediction model was built and compared with the previous models.
RESULTS: A total of 5277 subjects were studied and eight independent risk factors were identified including higher red blood cell distribution width (RDW), lower platelet count (PLT), lower percentage of lymphocyte (P-LYM), higher total bile acid (TBA), lower albumin, lower serum sodium level, higher degree of CALs (D-CALs) and younger age. The new predictive model showed an AUC of 0.74, sensitivity of 76% and specificity of 59%. For individual's risk probability of IVIG-resistance, an equation was given.
CONCLUSIONS: IVIG-resistance could be predicted by RDW, PLT, P-LYM, TBA, albumin, serum sodium level, D-CALs and age. The new model appeared to be superior to those previous models for KD population in Chongqing city.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30742060      PMCID: PMC6370794          DOI: 10.1038/s41598-019-39330-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Kawasaki disease (KD) is an acute autoimmune systemic vasculitis disease, mainly affecting young children and characterized by bilateral conjunctival inflammation, atypical rash, etc. The most serious consequence of KD is coronary artery lesions (CALs), which is associated with the prognosis of KD[1]. Prompt treatment with high-dose (2 g/kg) intravenous immunoglobulin (IVIG) could significantly reduce manifestations of KD and CALs. However, 10–20% of the KD patients are resistant to IVIG[2,3]. Thus, after initial IVIG administration, recrudescent or persistent fever may occur and further treatment is required at 48 hours after the initial use of IVIG, such as the second administration of IVIG, corticosteroids, etc[4]. The incidence of CALs in IVIG-resistant KD group was significantly higher than that in the IVIG-sensitive KD group (71% versus 5%, p < 0.0001)[5]. Moreover, studies have suggested that IVIG-resistance is an independent risk factor for giant coronary aneurysms[6,7]. Therefore, to early detect the IVIG-resistant KD patients and improve prognosis, it is important to identify the risk possibility of IVIG-resistance and take appropriate regimens early. The etiology and underlying biology of KD have not been completely elucidated. It is still a challenge for pediatricians to quickly diagnose KD, especially when diagnosing the children with atypical or incomplete KD. Many studies have tried to explore the methods to identify the disease more effectively and accurately. Previous studies reported that C-reactive protein, neutrophils, serum sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, erythrocyte sedimentation rate (ESR), age, etc. are the risk factors of IVIG-resistance[5,8-12]. Based on those risk factors, some prediction models for IVIG-resistant KD were established, including Fukunishi[3], Egami[8], Kobayashi[9] and Sano[5] scoring system from Japan and Yang[10] et al., Wang[11] et al. and Tang[12] et al. models from China. Those prediction methods, however, have limitations considering they are specific for Japan, North China and East China. As acknowledged, the risk factors of IVIG-resistance are likely to be different in different regions and populations[13-15]. The prediction models developed from the Japanese population may not prove to be accurate and sensitive enough when applied in the Chinese population. For instance, Kobayashi prediction model, which was developed based on a sample of 546 Japanese patients, showed rather unsatisfactory results when applied in Chinese population. The sensitivity and specificity of Kobayashi model were reported as 86.0% and 67.0% respectively when applied in the Japanese population while as 48.8% and 71.6% when applied in 1177 Chinese KD patients[15]. Although there are prediction models based on KD population in east China and north China, we still lack a prediction model specific for the population in Chongqing city, one of the biggest cities in western China, considering the very large area of China. In this study, we retrospectively reviewed 5277 KD patients from Chongqing, trying to identify risk factors and establish a new prediction model for IVIG-resistance in Chongqing city. The predictive ability, sensibility and specificity of our new model were further compared with the previously established models including Egami[8], Kobayashi[9] and Sano[5] scoring system from Japan and the model established by Yang[10] et al. from China

Materials and Methods

Patients

The KD patients who were hospitalized in Chongqing Children’s Hospital from October 2007 to December 2017 with discharge diagnosis of KD were enrolled into the study. According to the diagnostic guidelines of Kawasaki Disease Version 5[16], the diagnosis criteria were at least 5 days of fever accompanied by 4 or 5 items of the following clinical manifestations: bilateral conjunctival injection, changes in the lips and oral cavity, non-purulent cervical lymphadenopathy, polymorphous exanthema and changes in the extremities. The presence of three or fewer of the above manifestations was defined as incomplete KD. The inclusion criterion was KD as main diagnosis when the patients were first discharged. The exclusion criteria were incomplete KD and other diseases which are easily confused with KD, such as toddler’s idiopathic arthritis; those patients were also excluded who had been given IVIG treatment in other medical institutions before admission and who didn’t receive IVIG treatment during hospitalization.

Definition and data collection

IVIG-resistant KD was defined as the KD patients with a persistent or recurrence of fever >37.3 °C at any time during 48 hours to two weeks after initial IVIG treatment, and accompanied by one or more of the main symptoms[15]. The presence of coronary artery lesion was defined as coronary artery diameter ≥2.5 mm in patients aged 0–3 years old, ≥3.0 mm in patients aged 3–9 years old and ≥3.5 mm in patients older than 9 years old[17]. As for the degree of CALs (D-CALs), localized dilatation with internal diameter ≤4 mm, the dilatation with the internal diameter between 4 mm and 8 mm, and the dilatation with the internal diameter ≥8 mm were defined as slight CALs, moderate CALs and severe CALs respectively[18]. The patients were also classified according to age, that was age ≤6 months and age >6 months[8,12]. All demographic characteristics, imaging data and the laboratory data prior to the initial use of IVIG were collected. The demographic characteristics included age (month), sex, total cost and in-hospital time; imaging data prior to the initial use of IVIG included presence of coronary artery lesions and degree of CALs. The laboratory data included red blood cell(RBC), absolute value of red blood cell distribution (RDWa), red blood cell distribution width (RDW), packed cell volume, erythrocyte morphology, mean platelet volume (MPV), platelet distribution width (PDW), thrombocytocrit, platelet count (PLT), white blood cell (WBC), leucocyte morphology, mean corpuscular hemoglobin (MCH), lymphocyte count, percentage of lymphocyte (P-LYM), neutrophil count, percentage of neutrophil, monocyte, platelet-large-cell ratio (P-LCR), hemoglobin (HB), lymphocyte/neutrophil(LNR), urinary bile proto, leucocyte morphology, hematuria, urine specific gravity (low/normal/high), phagocyte, urine protein, white blood cell (stool), urobilirubin, gamma-glutamyl transpeptidase(GGT), alanine transaminase (ALT), aspartate aminotransferase (AST), lactic dehydrogenase(LDH), alkaline phosphatase (ALP), AST/ALT, total bile acid (TBA), direct bilirubin (DBIL), total bilirubin (TBIL), total protein (TP), albumin, prealbumin, globulin, creatinine, blood urea nitrogen (BUN), ketone body (KET), uric acid (UA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum inorganic phosphorus, serum sodium, serum potassium, serum magnesium, serum chlorine and serum calcium. If there were more than two laboratory reports concerning CRP, blood-routine, kidney function, urine-routine, electrolytes and liver function, we used the reports with the greatest value of CRP, neutrophils ratio, urea nitrogen, urinary protein and lowest albumin and sodium ion concentration. All those laboratory variables were routinely obtained in our clinical practice. For using the previous models, we kept the predictors in those models and re-estimate the coefficients with the current data set to build the models. The predictive ability of the new model was compared with the previous models including Kobayashi[9], Egami[8] and Sano[5] scoring systems from Japan and Yang prediction model[10] from China.

Statistical analysis

All data were presented as count with percentage for categorical variables and mean ± standard deviation (SD) for continuous variables. For the variables with miss rate <25%, multiple imputation was used. The Mann-Whitney U test was used for the comparison of the intergroup continuous variables; the Chi-square test was used for the comparison of categorical variables between the two groups. P < 0.05 was considered statistically significant. The selected variables significantly different between groups entered into the multivariate analyses. For building the prediction model of IVIG-resistant KD, 70% of the patients were randomly selected from the whole sample, including the IVIG–resistant KD and IVIG-responders, by generating random list of number; the other 30% of the patients’ data were used for testing the new model. To determine independent predictors of IVIG resistance, multivariate logistic regression analysis with least absolute shrinkage and selection operator (LASSO) was performed using the indicators with significant difference derived from the univariate analysis; the OR and 95% CI were calculated. The OR value was used to determine the score of an independent risk factor and build the new prediction model. Hosmer-Lemeshow goodness of fit (GOF) test was used to test the model, and p > 0.05 indicated that the prediction model fit the sample data. Receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to determine the predictive ability, sensitivity and specificity of the prediction model. To identify personal risk probability of IVIG-resistance that could be used in the nomogram, an equation was given. Data analysis was conducted using R Project for Statistical Computing (R version 3.4.1).

Ethic statement

The present study protocol was reviewed and approved by the Ethics Committee of the Children’s Hospital Affiliated to Chongqing Medical University, and with the its approval, this study required no conformed consent. All methods were performed in accordance with Declaration of Helsinki and the relevant guidelines.

Results

Sample collection

A total of 5277 subjects met the inclusion criteria and were enrolled into the study, including 348 cases of IVIG resistance (348/5277, 6.59%) and 4929 cases of IVIG responder (4929/5277, 93.41%). Fifty-seven variables were collected, including 4 demographic variables, 1 imaging variable and 52 laboratory variables. The variable, unconjugated bilirubin, was excluded due to its missing rate of 58%.

Comparison between IVIG-resistant KD and IVIG-responsive KD by univariate analysis

According to univariate analysis (Table 1), 24 variables were significantly higher in the IVIG-resistant group than in the IVIG-responsive group, including RDWa, RDW, erythrocyte morphology, MPV, PDW, Neutrophil count, Percentage of neutrophil, P-LCR, GGT, ALT, AST, lactic dehydrogenase, TBA, DBIL, TBIL, creatinine, BUN, UA, urine protein (positive), leucocyte morphology (urine, positive), urobilirubin (positive), white blood cell (stool, positive), CRP and D-CALs; 18 items were significantly lower in the IVIG-resistant group including RBC, PCV, thrombocytocrit, PLT, lymphocyte, HB, P-LYM, LNR, AST/ALT, TP, albumin, PALB, serum inorganic phosphorus, serum sodium, serum potassium, serum magnesium, serum calcium and age. Besides, the total cost and in-hospital time were significantly higher in IVIG-resistant group, indicating higher burden in IVIG-resistant KD patients.
Table 1

Univariate analysis comparison of clinical and laboratory indexes in IVIG responsive and resistant patients.

VariableIVIG responsiveIVIG resistantP-value
NMean ± SD/Counts (%)NMean ± SD/Counts (%)
Blood test
Red blood cell count, 1012/L40143.98 ± 0.443063.89 ± 0.470.001
Absolute value of Red blood cell Distribution, fL372740.30 ± 4.3428741.12 ± 4.730.002
Red blood cell distribution width, %399013.89 ± 1.6830114.30 ± 2.13<0.001
Packed cell volume, %401331.99 ± 3.3830631.09 ± 3.70<0.001
Erythrocyte morphology (normal/abnormal)*3815245 (0.06)29830 (0.10)0.021
Mean platelet volume, fL37779.90 ± 1.0829210.11 ± 1.210.004
Platelet distribution width, fL388211.48 ± 2.1929711.87 ± 2.500.002
Thrombocytocrit, %37150.45 ± 0.562800.38 ± 0.52<0.001
Platelet count, 109/L4014384.18 ± 155.44306338.13 ± 164.52<0.001
White blood cell, 109/L401315.31 ± 6.2430615.53 ± 6.400.626
Mean Corpuscular Hemoglobin, pg384626.28 ± 2.1029926.14 ± 2.160.206
Lymphocyte count, 109/L37603.70 ± 2.022932.97 ± 2.09<0.001
Percentage of lymphocyte40140.26 ± 143060.2 ± 0.13<0.001
Neutrophil count, 109/L392710.84 ± 5.6330011.75 ± 5.650.004
Percentage of neutrophil40140.69 ± 0.153060.75 ± 0.15<0.001
Monocyte count, 109/L36860.42 ± 0.302850.42 ± 0.350.258
Platelet-large-cell ratio, %364124.15 ± 8.1528225.78 ± 8.660.001
Hemoglobin, g/l4014104.26 ± 11.28306101.26 ± 12.05<0.001
Lymphocyte/neutrophil,37570.47 ± 0.512930.35 ± 0.42<0.001
Urine test
Urinary bile proto (positive)*4536100 (0.02)32912 (0.04)0.135
Leucocyte morphology (positive)*395842 (0.01)3018 (0.03)0.028
Hematuria (positive)*4536282 (0.06)32922 (0.07)0.824
Proportion (normal/high)*45363014/200 (0.66/0.044)329211/23 (0.64/0.07)0.095
Phagocyte (positive)*46011 (0.00)3301 (0.00)0.300
Urine protein (positive)*4536482 (0.11)32971 (0.22)<0.001
Urobilirubin (positive)*453697 (0.02)32931 (0.09)<0.001
Stool test
White blood cell (positive)*4601398 (0.09)33040 (0.12)0.041
Biochemical test
Glutamyltranspeptidase, U/L455084.47 ± 110.83312118.00 ± 121.52<0.001
Alanine transaminase, IU/L455068.13 ± 99.1631290.08 ± 117.16<0.001
Aspartate aminotransferase, IU/L473549.44 ± 90.9733663.59 ± 83.64<0.001
Lactic dehydrogenase, IU/L4736298.33 ± 153.10336316.63 ± 127.080.007
Alkaline phosphatase, IU/L4550182.97 ± 127.32312184.18 ± 92.160.332
AST/ALT45501.17 ± 0.833121.05 ± 0.780.006
Total bile acid, umol/L381620.56 ± 40.3424748.72 ± 77.35<0.001
Direct bilirubin, umol/L41875.22 ± 10.0328010.94 ± 17.53<0.001
Total bilirubin, umol/L454510.20 ± 13.0831218.92 ± 25.03<0.001
Total Protein, g/L455059.78 ± 6.8431258.32 ± 9.24<0.001
Albumin, g/L455036.92 ± 4.7631234.16 ± 5.94<0.001
Prealbumin, mg/L380564.00 ± 38.4724454.85 ± 39.58<0.001
Globulin, g/L455022.86 ± 5.2331224.16 ± 7.970.375
Creatinine, umol/L442525.91 ± 15.4630329.75 ± 22.540.004
Blood urea nitrogen, mmol/L44242.81 ± 1.363023.50 ± 2.55<0.001
Ketone body*,45360.50 ± 0.993290.43 ± 0.910.469
Uric acid, umol4423208.08 ± 81.64303224.13 ± 100.270.036
Inflammatory factor
C-reactive protein, mg/L386960.78 ± 52.3229673.28 ± 56.73<0.001
Erythrocyte sedimentation rate, mm/L440366.50 ± 32.3232263.33 ± 32.820.074
Ion
Serum inorganic phosphorus, mmol/L43941.31 ± 0.293061.24 ± 0.33<0.001
Serum sodium, mmol/L4397137.26 ± 3.17306135.90 ± 3.95<0.001
Serum potassium, mmol/L43974.23 ± 0.663064.06 ± 0.77<0.001
Serum magnesium, mmol/L43950.92 ± 0.113060.89 ± 0.12<0.001
Serum chlorine, mmol/L4395101.18 ± 3.73306100.84 ± 3.930.350
Serum calcium, mmol/L41082.29 ± 0.162772.23 ± 0.16<0.001
Imaging
Degree of coronary artery lesions (slight/moderate/severe)*37451497/212/24 (0.40/0.06/0.01)260135/39/3 (0.52/0.15/0.01)<0.001
Demographics
Age, month492831.80 ± 24.3234829.69 ± 25.680.016
Sex (female)*49281893 (0.38)348116 (0.33)0.067
Total costs, RMB492911450.25 ± 3646.8234819637.15 ± 9207.81<0.001
In-hospital time, day49297.65 ± 2.7534813.33 ± 6.48<0.001

ALT: Alanine transaminase; AST: Aspartate aminotransferase; *for categorical variables; N: number of sample; SD: standard deviation; W value for Wilcoxon-Mann-Whitney test; χ2 value for chi-square test.

Univariate analysis comparison of clinical and laboratory indexes in IVIG responsive and resistant patients. ALT: Alanine transaminase; AST: Aspartate aminotransferase; *for categorical variables; N: number of sample; SD: standard deviation; W value for Wilcoxon-Mann-Whitney test; χ2 value for chi-square test.

Analysis of independent risk factors and establishment of predicting model

For multiple logistic regression analysis, the variables with statistical significance derived from univariate analysis were further selected by LASSO constraints in order to find the optimal value of lambda by balancing accuracy and simplicity. The result suggested that the log of the optimal value of lambda was eleven. Among the eleven variables, eight indicators presented statistical significance and were used for multivariate logistic regression analysis (Table 2). The independent risk factors for IVIG-resistant KD were higher RDW, lower platelet count, lower P-LYM, higher TBA, lower albumin, lower serum sodium level, higher degree of CALs and younger age. The OR values (95%Cl) of those risk factors were listed in Table 2.
Table 2

The OR (odds ratio) values of the independent risk factors for IVIG-resistant Kawasaki disease.

Risk factorsMultiple logistic regression analysis after LASSOMultiple logistic regression analysis using the nine indicators with statistical significance
OR value (95% confidence interval)P-valueOR value (95% confidence interval)P-value
RDW1.181 (1.099–1.266)<0.0011.189 (1.106–1.274)<0.001
PLT0.999 (0.998–1.000)0.0480.999 (0.998–1.000)0.013
P-LYM0.066 (0.017–0.246)<0.0010.052 (0.013–0.193)<0.001
TBA1.004 (1.002–1.007)0.0011.006 (1.003–1.008)<0.001
Na0.954 (0.914–0.997)0.0340.946 (0.907–0.988)0.011
Albumin0.942 (0.916–0.968)<0.0010.940 (0.915–0.967)<0.001
D-CALs12.255 (1.654–3.107)<0.0012.197 (1.616–3.019)<0.001
D-CALs22.703 (1.550–4.587)<0.0012.815 (1.630–4.738)<0.001
D-CALs35.085 (1.099–17.078)0.0175.696 (1.234–19.078)0.010
BUN1.071 (0.996–1.149)0.057//
Urobilirubin1.444 (0.727–2.804)0.285//
Urine protein1.385 (0.929–2.027)0.101//
Age0.462 (0.302–0.726)0.0010.478 (0.313–0.750)0.001

LASSO, least absolute shrinkage and selection operator; RDW, red blood cell distribution width; PLT, lower platelet count; P-LYM, percentage of lymphocyte; TBA, total bile acid; Na, serum sodium level; D-CALs1, slight degree of coronary artery lesions; D-CALs2, moderate degree of coronary artery lesions; D-CALs3, severe degree of coronary artery lesions; BUN, blood urea nitrogen.

The OR (odds ratio) values of the independent risk factors for IVIG-resistant Kawasaki disease. LASSO, least absolute shrinkage and selection operator; RDW, red blood cell distribution width; PLT, lower platelet count; P-LYM, percentage of lymphocyte; TBA, total bile acid; Na, serum sodium level; D-CALs1, slight degree of coronary artery lesions; D-CALs2, moderate degree of coronary artery lesions; D-CALs3, severe degree of coronary artery lesions; BUN, blood urea nitrogen. Based on the above result, a nomogram was derived for personal risk probability of IVIG-resistance (Fig. 1). The underlying logistic model is given by the following equation:
Figure 1

The nomogram for personal risk probability of intravenous immunoglobin-resistant Kawasaki disease. As for age, the patients were classified as age ≤6 months and age >6 months. The risk score represents probability of intravenous immunoglobin-resistance. RDW, RBC; PLT, platelet count; P-LYM, percentage of lymphocyte; TBA, total bile acid; ALB, albumin; Na, serum sodium; D-CALs, degree of coronary artery lesions.

The nomogram for personal risk probability of intravenous immunoglobin-resistant Kawasaki disease. As for age, the patients were classified as age ≤6 months and age >6 months. The risk score represents probability of intravenous immunoglobin-resistance. RDW, RBC; PLT, platelet count; P-LYM, percentage of lymphocyte; TBA, total bile acid; ALB, albumin; Na, serum sodium; D-CALs, degree of coronary artery lesions. Thus, individual risk probability of IVIG-resistance could be identified. The coefficients indicate the contribution of the variables. Take RDW for an example, when the other variables are fixed, the odds ratio of having IVIG resistance increases by 18.9% (exp(0.173) − 1 = 1.189 − 1 = 0.189) with one unit increase in RDW. The increase unit in PLT, P-LYM, Na, albumin and age with negative coefficients, would decrease the odds ratio of IVIG-resistant KD; the increase of RDW, TBA, GLB and D-CALs with positive coefficients would increase the likelihood of having IVIG-resistance. The McFadden’s R squared was 0.1223 for this model. For model testing, 30% of the total cohort were applied to the new prediction model. GOF test indicated that the prediction model fit the sample data (χ2 = 2.3227, p = 0.508). The new predictive model for IVIG-resistance showed an AUC of 0.74 (Fig. 2), sensitivity of 76% and specificity of 59%. Multiple testing was performed to further evaluate the validity of the new prediction model, and the AUCs were shown in Fig. 3. The AUC on average was 0.72 (range 0.65–0.80), indicating the value of AUC was valid.
Figure 2

ROC and AUC of the prediction models for IVIG-resistance. The new predictive model for IVIG-resistance showed an AUC of 0.74, Compared with previous IVIG-resistant scoring systems, the new model presented a higher AUC value than the Kobayashi (AUC = 0.68), Egami (AUC = 0.65), Sano (AUC = 0.55) and Yang (AUC = 0.67) methods. ROC, receiver-operator characteristic curves; AUC, area under the curve.

Figure 3

AUCs of the new model by multiple testing. The AUC values of the new model tested by using the randomly-selected 30% of the whole subjects. The AUC on average was 0.72 (range 0.65–0.80).

ROC and AUC of the prediction models for IVIG-resistance. The new predictive model for IVIG-resistance showed an AUC of 0.74, Compared with previous IVIG-resistant scoring systems, the new model presented a higher AUC value than the Kobayashi (AUC = 0.68), Egami (AUC = 0.65), Sano (AUC = 0.55) and Yang (AUC = 0.67) methods. ROC, receiver-operator characteristic curves; AUC, area under the curve. AUCs of the new model by multiple testing. The AUC values of the new model tested by using the randomly-selected 30% of the whole subjects. The AUC on average was 0.72 (range 0.65–0.80).

Comparison between the new-established model and the previous scoring systems

Compared with previous IVIG-resistant scoring systems, the new model (AUC = 0.74) presented a higher AUC value than the Kobayashi (AUC = 0.68), Egami (AUC = 0.65), Sano (AUC = 0.55) and Yang (AUC = 0.67) methods. Those previous scoring systems were applied to the cohort in this study, and the result showed that sensitivity and specificity of the new prediction model were better than those previous scoring systems (Table 3).
Table 3

The predictive ability of the new model and the previous models.

The new modelKobayashi modelEgami modelSano modelYang model
Sensitivity0.760.750.720.950.67
(95% CI)(0.70–0.81)(0.69–0.80)(0.66–0.77)(0.92–0.98)(0.61–0.73)
Specificity0.590.480.440.10.57
(95% CI)(0.57–0.60)(0.47–0.50)(0.42–0.46)(0.09–0.11)(0.55–0.58)

AUC, area under the curve; CI, confidence interval.

The predictive ability of the new model and the previous models. AUC, area under the curve; CI, confidence interval.

Discussion

Currently, the treatment of KD mainly depends on high dose of IVIG, however, IVIG-resistant KD is not sensitive to IVIG and additional treatment cannot quickly and effectively reduce vascular inflammation after the initial use of IVIG or after the diagnosis of IVIG-resistance[19-21]. Thus, it results in increased incidence of CALs, which is harmful to the KD prognosis. It would possibly reduce the CALs incidence in the IVIG-resistant KD patients if additional treatment is adopted early before the initial use of IVIG[5]. Therefore, there is an urgent need to build a prediction model for IVIG-resistant KD with high predictive ability for specific populations in different areas. Here, we reviewed 5277 KD patients from Chongqing city, in West China, and built a new prediction model which appeared to be superior to those previous models when applied in this KD population. In this study, the percentage of IVIG-resistance was 6.25%, which was far below the percentage of 10%-20% in the studies of Fukunishi[3] et al. and Sleeper[2] et al. and was close to the percentage of 5.1% in Tang’s study[12] and 5.0% in Qian’s[22]. This might be attributed to the different study populations, the bigger sample size of this study, and the definition of IVIG-resistance. In Sano’s study, IVIG-resistance was defined as persistent fever >24 hours after the completion of initial IVIG infusion while in our study it’s defined as persistent fever >48 hours and duration of initial IVIG use ≥5 days. The initial incidence of CALs judged by absolute diameter was 68% in IVIG-resistant group and 47% in IVIG-responsive group in this study. The initial CALs incidence in IVIG-resistant group was close to Han’s study[23] and was much higher than Chantasiriwan’s study[24], but the incidences in IVIG-responsive groups were similar to theirs. There were several prediction models for IVIG-resistant KD. The risk factors in those models include age of month <6; IVIG treatment within 4 days of illness; abnormal first echocardiographic results; higher levels of CRP, ALT, AST, PCT, neutrophil ratio, percentage of band cell, TBIL and LDH; and lower levels of PLT, serum sodium, hemoglobin and pericardial effusion, etc[9,11,12,15,25-27]. However, those models could not present high predictive ability in populations from different regions. The independent risk factors reported in the previous prediction model, such as CRP, AST, ALT, TBL, NEU%, ALB, GGT, LDH and LNR were significantly different between IVIG-responsive and IVIG-resistant group in our study, but they failed to enter in the final logistic regression model[3,5,8-11]. Besides, the results of univariate analysis may be different in different populations between IVIG-responsive and IVIG-resistant group. For instance, GGT level was significantly different between the two groups in our and Wang’s study, while wasn’t in Yang’s and Kobayashi’s study. Serum chlorine level was significantly different between the IVIG-responders and the IVIG-resistant in Kobayashi’s study, while was not in our and Wang’s study. AST was an independent risk factor in Kobayashi’s and Sano’s study and ALT was an independent risk factor in Egami’s study, but those two factors didn’t show statistical difference in the univariate analysis in Yang’s study[5,8-11]. It might be attributed to that KD pathology is related with genetic polymorphisms, and the reported genetic determinants of KD were different in various populations[28]. The genetic polymorphisms and unknown etiology might make the risk factors of IVIG-resistant different in different populations. We expected to identify new risk factors of IVIG-resistant KD and establish a more accurate prediction model for Chongqing city. Therefore, this study collected demographic, imaging and laboratory information from 5277 KD patients as completely as possible. The sample size and the variables included in our study were much larger than previous IVIG-resistant KD prediction models. In the present study, a total of 57 variables were successfully collected and included in the univariate analysis, of which 42 factors showed significant difference between the two groups. Eight independent risk factors were identified, among which RDW, P-LYM and D-CALs were not identified as predictive indicators for IVIG-resistance in previous studies. We also found that some new factors were significantly different between the two groups, including PCV, MPV, PDW, thrombocytocrit, P-LCR, lymphocyte/neutrophil, urine protein, urobilirubin, AST/ALT, PALB, serum inorganic phosphorus, serum magnesium and serum calcium. But those were not independent risk factors. In this study, we didn’t include the patients who received initial IVIG treatment within 4 days of illness because the diagnosis criteria of Kawasaki disease required fever duration ≥5 days. Several studies reported that the platelet counts decreased in IVIG-resistant KD patients[9,11,29]. In our study, we found platelet changed in morphology in addition to the decreased counts in IVIG-resistance group. The reduction of platelets might be associated with CAA-induced platelet consumption, which was followed by a compensatory change in platelet morphology, with an increased volume of platelet and a larger PDW. Urinary protein was higher in IVIG-resistance group than in IVIG-responsive group, which might imply a more severe glomerular vasculitis and increased glomerular vascular permeability in IVIG-resistant KD patients. Besides the increase of ALT, AST, TBIL and LDH, we also observed higher urobilirubin and lower PALB in IVIG-resistant KD group, which suggested that the patients with IVIG-resistance might have more severe systemic inflammation and vasculitis in liver[5]. As stated in the 5-minute Pediatric Consult (Second Edition)[30], the concentration of serum inorganic phosphorus and serum sodium decreased in patients with KD and low concentration serum potassium was related with CAA[31]. The significantly lower concentration of serum inorganic phosphorus, serum potassium, serum magnesium, serum calcium and serum sodium and higher concentration of BUN were observed in IVIG-resistant group in our study, which indicated that kidney vasculitis might exert negative effect on renal function and tubular reabsorption. The final risk factors selected to undergo multivariate analysis for predicting IVIG-resistance, including RDW, platelet count, P-LYM, TBA, albumin, serum sodium level, D-CALs and age. Among those variables, TBA, serum sodium, albumin, platelet count and age of month have been reported in previous studies. The increased RDW was related to anemia, which was consistent with Durongpisitkul’s study. The reduced P-LYM represented higher percentage of neutrophil in blood and more severe inflammation, which was also reported in the studies of Durongpisitkul et al. and Wang et al.[11,32]. The new model for IVIG-resistant KD prediction was generated based on those risk factors, with the AUC of 0.74, sensitivity of 76% and specificity of 59%. The AUC value, sensitivity and specificity in this study showed better accuracy compared with the previous models when applied in the population from Chongqing city. This study has considered more medical information besides the factors included in the previous prediction models, in order to find the potential hint of the disease. The factors including RDW, D-CALs and P-LYM were rarely mentioned in previous prediction models. In the future, we will conduct a prospective study to further evaluate the effectiveness of this new model. Still, this study has some limitations. Firstly, it’s a retrospective study in a single center. Secondly, multiple clinical teams participated in the care and measurement of the patients. Thirdly, due to the lack of patients’ height data, no mean body-surface-area (BSA) adjusted Z-score was available; we will take it into consideration in our future study. Last, some data items were missing, which might result in bias in statistical analysis; for the variables with miss rate <25%, multiple imputation was done to decrease bias in this study. With the large sample size, we thought we could still draw a relatively valid conclusion.

Conclusion

The IVIG-resistance could be predicted using the values of RDW, PLT, P-LYM, TBA, ALB, serum sodium level, D-CALs and age. The new model of predicting IVIG-resistant KD appeared to be superior to those previous prediction models for the KD population in Chongqing city. Further study is necessary to validate the utility of this new model.
  31 in total

1.  Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

Authors:  P A Brogan; A Bose; D Burgner; D Shingadia; R Tulloh; C Michie; N Klein; R Booy; M Levin; M J Dillon
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

2.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Authors:  M Fukunishi; M Kikkawa; K Hamana; T Onodera; K Matsuzaki; Y Matsumoto; J Hara
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

3.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease.

Authors: 
Journal:  Pediatr Int       Date:  2005-12       Impact factor: 1.524

4.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

5.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

6.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition).

Authors:  Mamoru Ayusawa; Tomoyoshi Sonobe; Shigeru Uemura; Shunnichi Ogawa; Yoshikazu Nakamura; Nobuyuki Kiyosawa; Masahiro Ishii; Kensuke Harada
Journal:  Pediatr Int       Date:  2005-04       Impact factor: 1.524

7.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

8.  Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease.

Authors:  R K Han; E D Silverman; A Newman; B W McCrindle
Journal:  Arch Pediatr Adolesc Med       Date:  2000-07

9.  Immunoglobulin failure and retreatment in Kawasaki disease.

Authors:  K Durongpisitkul; J Soongswang; D Laohaprasitiporn; A Nana; C Prachuabmoh; C Kangkagate
Journal:  Pediatr Cardiol       Date:  2002-12-04       Impact factor: 1.655

10.  Intravenous gamma-globulin treatment in Kawasaki disease.

Authors:  K Harada
Journal:  Acta Paediatr Jpn       Date:  1991-12
View more
  11 in total

1.  Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy.

Authors:  Takashi Ishikawa; Yasuyuki Wada; Hiroyuki Namba; Toshinao Kawai
Journal:  Clin Rheumatol       Date:  2021-06-19       Impact factor: 2.980

2.  Combined IFN-β and PLT Detection Can Identify Kawasaki Disease Efficiently.

Authors:  Kan Huijuan; Dong Yaping; Wang Bo; Hou Miao; Qian Guanghui; Yan Wenhua
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

3.  A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old.

Authors:  Shu Wu; Yuan Long; Selena Chen; Yaqian Huang; Ying Liao; Yan Sun; Qingyou Zhang; Chunyu Zhang; Hui Yan; Jianguang Qi; Xueqin Liu; Yonghong Chen; Yong Zhang; Junbao Du
Journal:  Front Pediatr       Date:  2019-12-11       Impact factor: 3.418

4.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

5.  Comparison of Machine Learning Models for Prediction of Initial Intravenous Immunoglobulin Resistance in Children With Kawasaki Disease.

Authors:  Yasutaka Kuniyoshi; Haruka Tokutake; Natsuki Takahashi; Azusa Kamura; Sumie Yasuda; Makoto Tashiro
Journal:  Front Pediatr       Date:  2020-12-03       Impact factor: 3.418

Review 6.  Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives.

Authors:  Piotr Buda; Joanna Friedman-Gruszczyńska; Janusz Książyk
Journal:  Front Med (Lausanne)       Date:  2021-11-30

7.  Serum sodium level associated with coronary artery lesions in patients with Kawasaki disease.

Authors:  Hiroya Masuda; Ryusuke Ae; Taka-Aki Koshimizu; Masami Matsumura; Koki Kosami; Kanako Hayashida; Nobuko Makino; Yuri Matsubara; Teppei Sasahara; Yosikazu Nakamura
Journal:  Clin Rheumatol       Date:  2021-08-07       Impact factor: 2.980

8.  Prognostic value of pretreatment prognostic nutritional index in intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Gang Li; Xiumei Xu; Pengyuan Chen; Rumeng Zeng; Bin Liu
Journal:  Heart Vessels       Date:  2021-03-08       Impact factor: 2.037

9.  Crucial transcripts predict response to initial immunoglobulin treatment in acute Kawasaki disease.

Authors:  Zhimin Geng; Jingjing Liu; Jian Hu; Ying Wang; Yijing Tao; Fenglei Zheng; Yujia Wang; Songling Fu; Wei Wang; Chunhong Xie; Yiying Zhang; Fangqi Gong
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

10.  Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study.

Authors:  Yu Yan; Lina Qiao; Yimin Hua; Shuran Shao; Nanjun Zhang; Mei Wu; Lei Liu; Kaiyu Zhou; Xiaoliang Liu; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2021-09-25       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.